Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 23 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 11534430

    Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs

    Lutonix, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  2. US 11529395

    Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

    Takeda Pharmaceutical Company Limited · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  3. US 11524053

    Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

    The Regents of the University of California · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  4. US 11524013

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  5. US 11517564

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted
  6. US 11512309

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  7. US 11512141

    Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment

    The Board of Regents of the University of Texas System · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  8. US 11510887

    Sobetirome in the treatment of myelination diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  9. US 11512052

    Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  10. US 11512312

    Treatment of Fuchs' endothelial corneal dystrophy

    The Board of Regents of the University of Texas System · Granted Nov 29, 2022 · Expires Nov 24, 2042

    granted
  11. US 11505604

    Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  12. US 11505572

    Therapeutics for the treatment of glaucoma

    Regents of the University of Minnesota · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  13. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  14. US 11505574

    Modulation of P53 for the treatment of cancer

    The Regents of the University of California · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  15. US 11497739

    Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with a-beta peptide aggregation

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  16. US 11497725

    Treatment for obesity

    AXSOME MALTA LTD. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  17. US 11497740

    Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

    The Board of Regents of the University of Texas System · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  18. US 11497736

    Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  19. US 11491212

    Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

    Catalyst Biosciences, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  20. US 11492643

    Methods and compositions for treatment of a genetic condition

    Sangamo Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  21. US 11484523

    Compositions for prevention and treatment of symptoms associated with alcohol consumption

    Purple Biosciences LLC · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  22. US 11484511

    Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer

    KOREA UNITED PHARM. INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted
  23. US 11478571

    Synthetic hydrogel carriers for cellular structures, generation of organoids, and treatment of tissue injury

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  24. US 11479530

    Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

    The Regents of the University of California · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted